ArticleFrontiers in tuberculosis2024
Clinical and laboratory risk factors for pulmonary tuberculosis recurrence in three pooled Indian cohorts.
Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Point-of-Care Prediction Tool for Recurrent Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Epidemiological analysis and risk factors of recurrent pulmonary tuberculosis in Western Zhejiang Province, China (2007-2024).Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Some individuals with drug-susceptible pulmonary tuberculosis (PTB) experience tuberculosis recurrence. To evaluate the incidence of and risk factors for recurrence following completion of antituberculosis therapy, we pooled data from three prospective observational Indian PTB cohorts with 1164 individuals ≥14 years old included in our analysis. Ninety-five (8%) experienced recurrence with an 8.5 cases/100 person-years recurrence incidence rate (95% confidence interval 6.9-10.3) and a median time to recurrence of 6 months. On multivariable logistic regression, month 2 culture positivity (aHR 2.06; 95% CI 1.17-3.63), BMI <17 mg/kg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.